

Article type:

Submitted version – Preprint

Full citation:

Rosa Calvello; Antonella Aresta; Adriana Trapani; Carlo Zambonin; Antonia Cianciulli; Rosaria Salvatore; Maria Lisa Clodoveo ; Filomena Corbo; Carlo Franchini ; Maria Antonietta Panaro
Bovine and soybean milk bioactive compounds: effects on inflammatory response of human intestinal Caco-2 cells. *Food Chemistry*, 2016, 210, 276-285.

Publication History:

Article history: Received 21 November 2015

Received in revised form 19 March 2016

Accepted 18 April 2016

Available online 19 April 2016

Source name:

Food Chemistry

ISSN: 2590-1575

Editor:

Elsevier

Link for final version:

<https://doi.org/10.1016/j.foodchem.2016.04.067>

This is a submitted-preprint version of an accepted manuscript. Note that revisions and technical editing may introduce changes to the manuscript text and/or graphics which could affect content. To access to the final version, click the link above.

1 **Title:**

2 **Bovine and soybean milk bioactive compounds: effects on inflammatory response of human**
3 **intestinal Caco-2 cells.**

4 **Running title: Milk bioactive compounds and their effects on Caco-2 cells**

5 **Authors:**

6 Rosa Calvello^{1§}; Antonella Aresta^{2§}; Adriana Trapani³; Carlo Zambonin²; Antonia Cianciulli¹,
7 Rosaria Salvatore¹; Maria Lisa Clodoveo⁴; Filomena Corbo^{3*}; Carlo Franchini³; Maria Antonietta
8 Panaro¹

9 **Affiliations:**

10 ¹*Department of Biosciences, Biotechnologies and Biopharmaceuticals - University of Bari, via*
11 *Orabona 4, 70126 Bari-Italy*

12 ²*Department of Chemistry – University of Bari, via Orabona 4, 70126 Bari-Italy*

13 ³*Department of Pharmacy-Pharmaceutical Sciences - University of Bari, via Orabona 4, 70126*
14 *Bari-Italy*

15 ⁴*Department of Agro-Environmental and Territorial Sciences – University of Bari, via Orabona 4,*
16 *70126 Bari-Italy*

17

18 [§]These authors contributed equally to this work

19 **E-mail address of each author:**

20 rosa.calvello@uniba.it; antonellamaria.aresta@uniba.it; marialisa.clodoveo@uniba.it;

21 filomena.corbo@uniba.it; mariaantoinetta.panaro@uniba.it; adriana.trapani@uniba.it;

22 carlo.zambonin@uniba.it; antonia.cianciulli@uniba.it; carlo.franchini@uniba.it;

23 rosaria.salvatore@gmail.com

***Corresponding author:**

Filomena Corbo - Department of Pharmacy-Pharmaceutical Sciences, University of Bari, via
Orabona 4, 70126 Bari-Italy - filomenafaustinarina.corbo@uniba.it – Tel. +390805442746;

24 **ABSTRACT**

25 In this study, the effects of commercial bovine and soybean milks and their bioactive compounds,
26 namely genistein, daidzein and equol, on the inflammatory responses induced by lipopolysaccharide
27 (LPS) treatment of human intestinal Caco-2 cells were examined in terms of nitric oxide (NO)
28 release and inducible nitric oxide synthetase (iNOS) expression.

29 Both milks and their bioactive compounds significantly inhibited, in a dose-dependent manner, the
30 expression of (iNOS) mRNA as well as protein expression, resulting in a decreased NO production.

31 In addition, the activation of NF- κ B in LPS-stimulated intestinal cells was examined. In all cases it
32 was observed that cell pre-treatment before LPS activation inhibited the phosphorylation, as well as
33 the degradation, of the I κ B complex. Accordingly, quantification of bioactive compounds by solid
34 phase microextraction coupled with liquid chromatography has shown that they were absorbed,
35 metabolized and released by Caco-2 cells in culture media.

36 In conclusion, we have demonstrated that milks and compounds tested are able to reduce LPS-
37 induced inflammatory responses from intestinal cells, interfering with the activation of NF- κ B
38 dependent molecular mechanisms.

39

40 **Keywords:** Bovine and Soybean milks; isoflavones-aglycones; equol, Caco-2 cells; SPME-HPLC-
41 UV/DAD.

42

43 1. INTRODUCTION

44 The mucosal surface of the intestinal tract is a complex ecosystem combining the gastrointestinal
45 epithelium, immune cells and resident microbiota. The intestinal mucosa is not only involved in
46 absorbing nutrients, but it is constantly exposed to an array of foreign antigens. Robust protective
47 immune responses must be generated in response to pathogenic insult, leading to the production of
48 mediators (cytokines, growth factors, adhesion molecules, etc.) which promotes and amplifies the
49 inflammatory response (Kaser et al., 2010).

50 Whereas an adequate inflammatory response is essential to protect the host from pathogens attack,
51 an excessive production of inflammatory mediators may alter the homeostasis of bowel epithelium.
52 Inflammatory bowel disease (IBD), including Crohn's disease (CD), and ulcerative colitis (UC), are
53 chronic inflammatory disorders of the gut with complex etiologies (Kaser et al., 2010). One of the
54 worst complications of IBD is the ultimate development of colon cancer. Therefore, the
55 employments of agents that block the inflammatory responses have been particularly successful in
56 IBD therapy. Currently there is no cure for IBD, thus the search for new molecules able to control
57 IBD and their delivery to the site of inflammation are the goal of many researchers.

58 Flavonoids, natural phenolic compounds, are normal constituents of the human diet and are known
59 for a variety of biological activities. Some of them act as enzyme inhibitors and antioxidants, and
60 have been reported to have anti-inflammatory properties. However, the molecular mechanisms
61 explaining how flavonoids suppress the inflammatory response are not yet known in detail (Panaro
62 et al., 2012; Cianciulli et al., 2012; Havsteen, 2002).

63 Genistein, an isoflavone very abundant in soy (*Glycine max*), has been found to play an important
64 role in the prevention of various chronic diseases including cancer (Sarkar and Li, 2003). Various
65 epidemiological, *in vitro* and animal studies have evaluated the anti-cancer, cardio-protective, anti-
66 osteoporotic, antioxidant, anti-inflammatory activities of genistein. It has been also associated with
67 the inhibition of tyrosine-specific protein kinase in malignant cells (Caldarelli et al., 2005; Zhang et

68 al., 2008; Park et al., 2010; Rusin et al., 2010). It was reported that genistein modulates the
69 expression of NF- κ B and MAPK (p-38 and ERK1/2), thereby attenuating D-Galactosamine induced
70 fulminant hepatic failure in Wistar rats (Ganai et al., 2015)

71 Like genistein, daidzein is an isoflavone physiologically active that occurs mainly in free and
72 glycosylated form in soy. Isoflavone glucosides of daidzein and genistein, namely daidzin and
73 genistin, are more abundant and soluble but less active than free forms (Di Cagno et al., 2010). In
74 the gastrointestinal tract, each sugar-conjugated is hydrolysed by isoflavone β -glucosidase from gut
75 bacteria to release the aglycone and sugar part. Then, all free forms are rapidly absorbed,
76 metabolized or re-conjugated with sugars by intestinal epithelial cells to assure their utilization or
77 removal by the cells (Di Cagno et al., 2010). An interesting metabolite of daidzein is equol because
78 it has a greater structural similarity to estrogens than its parent (Antignac et al., 2004; Di Cagno et
79 al., 2010; Andres et al., 2011). It produces major effects on vascular reactivity, thrombosis, lipid
80 profiles and cellular proliferation (Andres et al., 2011).

81 As a result, it can be hypothesized that the dietary intake of isoflavones may be helpful in the
82 treatment of IBD. In this regard, bovine milk has been reported to have beneficial effects on
83 gastrointestinal health both in infants and in adults (Haug et al., 2007). Moreover, soy flavonoids
84 may have some benefits for people with intestinal inflammation beyond simply nutritional support.
85 Similarly, soy milk, the most popular alternative to cow's milk, could also possess anti-
86 inflammatory activity, which is suitable in IBD therapy.

87 The aim of this study is investigating the potential anti-inflammatory effects of bovine and soybean
88 milks, as well as of the equol, daidzein and genistein using an *in vitro* model of human intestinal
89 epithelial cells, Caco-2 cell line, submitted to Lipopolysaccharide (LPS) treatment as pro-
90 inflammatory stimulus. LPS, the principal component of the outer membrane of Gram-negative
91 bacteria, plays a pivotal role in triggering an early inflammatory response through the interaction of
92 several receptors for microbial products.

93 2. MATERIALS AND METHODS

94 2.1. Cell cultures and treatments

95 Caco-2 human colorectal cancer cells (ICLC HTL 97023) were obtained from Interlab Cell Line
96 Collection (Genoa, Italy). The cells were cultured in MEM medium supplemented with 10% fetal
97 bovine serum (FBS, UE approved origin), 100 U/mL penicillin, 100 µg/mL of streptomycin, L-
98 glutamine (2 mM), 1% nonessential amino acids (NEEA), referred to as complete medium (all
99 reagents were purchased from Life Technologies-Invitrogen, Milan, Italy).

100 Cultures were maintained at 37° C in an atmosphere with humidity containing 5% CO₂ and
101 expanded in tissue culture flasks (75 cm², BD Biosciences, USA), changing the medium daily. Caco-
102 2 cells were grown up to 80% confluency in 6-well cell culture plates.

103 For the experiments, cells were treated with *Salmonella enterica* serotype typhimurium LPS
104 (Sigma). Preliminary experiments were performed in order to establish the optimal dose (1 µg/mL)
105 of LPS and time of exposure to LPS (48 h). Before LPS stimulation, some wells were pre-treated
106 with different concentrations (5, 10, 50 µM) of daidzein (4',7-dihydroxyisoflavone, Sigma),
107 genestein (4', 5, 7-trihydroxyisoflavone, Sigma) and equol (dihydroxyisoflavone, Sigma) or with
108 different amounts (10, 30 and 50 µL) of the commercial (bovine or soy) milks. After 1h of
109 incubation at 37°C, cell cultures were then stimulated with endotoxin as previously indicated.
110 Untreated cells were used as control.

111 2.2. Cell Viability Assay

112 In order to test cells viability, we used MTT (3,4,5-dimethylthiazol-2-yl)-2-5-diphenyltetrazolium
113 bromide) assay, which is based on the reduction of MTT by the mitochondrial dehydrogenase of
114 intact cells to a purple formazan product. Briefly, cells (2.5×10^4) were seeded in a 96-well plate
115 (BD Biosciences, USA). After cell treatment, culture media were carefully removed and 100 µL of
116 0.5 mg/mL MTT in cell culture medium was added to each well and incubated for 4 h. Finally, 100
117 µL of 10% SDS, 0.01 M HCl solution was added to each well to dissolve the formed formazan

118 crystals. The amount of formazan was determined measuring the absorbance at 560 nm using a
119 microplate reader.

120 2.3. Quantitative analysis of equol, daidzein and genistein from different samples by SPME-HPLC- 121 UV/DAD method

122 In order to clarify the role of the isoflavones in the anti-inflammatory responses observed *in vitro*,
123 their concentration has been determined both in cell culture media and cell lysates, as well as in
124 bovine and soybean milk samples, by solid-phase micro-extraction coupled to liquid
125 chromatography (SPME-LC).

126 Milk was diluted 1:100 with a 0.2% formic acid - 30% (w/v) NaCl solution and stirred for 30 min
127 before SPME. An enzymatic deconjugation was accomplished to estimate the total amount of each
128 isoflavone-aglycone. A solution (0.75 mL), containing 10 mg/ml β -glucosidase (≥ 2 units/mg solid,
129 Sigma-Aldrich, Milano, Italy) in acetate buffer (0.1 M, pH 5.0), was added to 0.75 ml of milk, and
130 incubated overnight at 37°C. Finally, 30 μ L, pure or diluted (1:10), were subjected to SPME.
131 Culture media, taken from wells after 48 h, were diluted 1:10 with 0.2% formic acid with 30% NaCl
132 before SPME analysis. Analytes extraction from the cell lysate supernatant was performed by
133 diluting an aliquot of each sample 1:4 with saline after protein total assay. Then, variable aliquots
134 were transferred into a vial containing the usual extraction mixture, in order to have 1.5 mL of
135 solution at proteins total concentration of 0.025 mg/mL to be submitted to SPME analysis.

136 The SPME step was conducted in stirred solutions for 20 min using a 65 μ m PDMS-DVB fiber
137 (Supelco, Bellefonte, PA, USA). Desorptions were performed for 15 min in mobile phase in the
138 SPME interface before switching the injector valve in the inject position.

139 The LC-UV system was composed by a P2000 pump coupled with a UV6000LP photodiode array
140 (all Thermo Finnigan, San Jose, CA), a SPME manual interface (Supelco, Bellefonte, PA, USA), a
141 KinetexTM C18 (2.6 μ m, 100 x 4.6 mm i.d., Phenomenex, USA) column.

142 Instrumental conditions were as follows: isocratic elution using 0.05 % (v/v) formic acid in
143 acetonitrile/methanol/water (8:32:60, v/v/v) as mobile phase, flow rate 0.7 ml/min; detection
144 wavelengths were 260 and 280 nm (5 nm band-width).

145 The quantification of the analytes in bovine and soybean milk samples was performed with the
146 standard addition method.

147 Fortified samples were equilibrated at 37 °C in a water bath for 30 min before being processed as
148 described. Three replicates for each concentration, including blank, were made.

149 Calibration curves for the target analytes in Caco-2 cells culture media were constructed in the
150 range 0.015 - 20 µM. Fortified samples were diluted 1:10 in 0.2% formic acid at 30% NaCl before
151 analysis.

152 *2.4. Nitric oxide (NO) production*

153 Nitrite, a stable end-product of NO metabolism, was estimated using the Griess reaction. After
154 treatment of Caco-2 cells with LPS for 48 hours, culture media were collected and mixed (1:1v/v)
155 with the Griess reagent (1% sulfanilamide, 0.1% N-1-naphthylenediamine dihydrochloride, and
156 2.5% phosphoric acid) for 10 min at room temperature, followed by spectrophotometric
157 measurement at 550 nm. Nitrite concentrations in the culture media were determined by comparison
158 with a sodium nitrite standard curve and expressed as µmol/mL. To avoid interference by nitrites
159 possibly present in the medium, in each experiment the absorbance of the unconditioned medium
160 was assumed as the “blank”.

161 *2.5. Electrophoresis and Western Blotting*

162 After treatments, cells were lysed with lysis buffer [1% Triton X-100, 20 mM Tris-HCl, 137 mM
163 NaCl, 10% glycerol, 2 mM EDTA, 1 mM phenylmethylsulfonyl fluoride (PMSF), 20 µM leupeptin
164 hemisulfate salt, 0.2 U/ml aprotinin (all from Sigma-Aldrich)] for 30 min on ice. The lysate was
165 vortexed for 15-20 sec and then centrifuged at 12,800x g for 20 min; the protein concentration in
166 the supernatant was spectrophotometrically determined with Bradford's protein assay (Bradford,

167 1976). Protein samples were diluted with sample buffer (0.5 M Tris HCl pH 6.8, 10% glycerol, 10
168 % w/v SDS, 5% β 2-mercaptoethanol, 0.05% w/v bromophenol blue) and then boiled for 3 min.
169 Proteins (25 μ g/lane) and prestained standards (BioRad Laboratories, Hercules, CA, USA) were
170 loaded on 7% SDS precast polyacrylamide gels (BioRad Laboratories).
171 After electrophoresis, the resolved proteins were transferred from the gel to nitrocellulose
172 membranes. A blotting buffer [20 mM Tris/150 mM glycine, pH 8, 20% (v/v) methanol] was used
173 for gel and membrane saturation and blotting. A blocking solution [bovine serum albumin (BSA),
174 0.2%–5% (w/v), Tween-20,(0.05–0.1%), non fat dry milk (0.5–5%), Casein(1%), all from BioRad
175 Laboratories] was used in order to prevent nonspecific binding of unoccupied membrane sites.
176 Then, membranes were incubated in the dark with (1:200 diluted) primary antibody anti human
177 NOS II, anti human IKB α anti human pIKB α (all from Santa Cruz Biotechnology, Heidelberg,
178 Germany), for 60 min at room temperature. The membranes were washed with T-PBS (for 20 min,
179 3 times) and then incubated with the secondary antibody anti-human IgG diluted 1:2000,
180 horseradish peroxidase (HRP)-conjugate (Santa Cruz Biotechnology) for 60 min. Bands were
181 visualized with the chemiluminescence method (BioRad, Laboratories).

182 *2.6. Densitometric analysis*

183 The bands obtained after immunoblotting were submitted to densitometric analysis using ID Image
184 Analysis Software (Kodak Digital Science). Results were expressed as arbitrary units.

185 *2.7 Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) and quantitative real-time PCR* 186 *analyses.*

187 Briefly, total tissue RNA was extracted from treated and untreated cells by the Trizol isolation
188 reagent (Invitrogen, Milan, Italy) according to the manufacturer's instructions. Reverse
189 transcription was performed in a final volume of 20 μ L containing 3 μ g of total RNA, 40 U of
190 RNase Out (Invitrogen), 40 mU of oligo dT with 0.5 mM dNTP (PCR Nucleotide Mix, Roche
191 Diagnostics, Milan, Italy), and 40 U of Moloney Murine Leukemia Virus Reverse Transcriptase

192 (Roche Diagnostics). The reaction tubes were incubated at 37°C for 59 min, and then at 95°C for 5
193 min and at 4°C for 55 min. The cDNA obtained was then amplified by a thermal cycler (Eppendorf,
194 Milan, Italy) under the following conditions: 95°C for 1 min, 55°C for 1 min and 72°C for 1 min
195 (30 cycles of amplification). The reaction tube contained, in a final volume of 50 µL, 2 µL of
196 cDNA, 200 µM dNTP (PCR Nucleotide Mix, Roche Diagnostics), 4 U TaqDNA Polymerase
197 (Roche Diagnostics), 5µL of MgCl₂ buffer stock solution, and 50 pmol of the specific primers.
198 The mRNA levels of various genes were quantified using the SYBR Green QuantiTect RTPCR Kit
199 (Roche, South San Francisco, CA, USA). β-actin was used as endogenous reference. Data were
200 analyzed using the relative standard curve method according to the manufacturer's protocol. The
201 mean value of each gene after β-actin normalization at the time point showing the highest
202 expression was used as calibrator to determine the relative levels. The primers used for
203 amplification for iNOS (NCBI reference sequence NM_000625.4) were: forward primer 5'-
204 CGGCCATCACCGTGTTCCTCC-3'; reverse primer, 5'-TGCAGTCGAGTGGTGGTCCA-3'; and
205 for β-actin forward primer, 5'-GGCGGCACCACCATGTACCCT-3'; reverse primer, 5'-
206 AGGGGCCGGACTCGTCATACT-3'.

207 *2.8. Data Presentation and Statistical Analysis*

208 Student's t test and analysis of variance (one-way ANOVA) on the results of at least five
209 independent biological replicates were performed. Values of $p < 0.05$ were considered statistically
210 significant.

211 **3. RESULTS**

212 *3.1. Viability test*

213 The MTT assay was used in order to test the viability of cells exposed to isoflavones and/or
214 endotoxin treatment. Low concentrations of all tested isoflavones resulted no toxic for Caco-2 cells
215 in comparison with untreated cells, whereas relatively higher concentration (50 µM) were resulted
216 cytotoxic (Fig. 1, Panel A). We also found that the viability of cells exposed for 48 h to 1 µg/mL LPS

217 was significantly reduced in comparison to controls (Fig. 1, Panel B). Interestingly, the viability of
218 LPS stimulated cells was significantly improved after 1h pre-treatment with isoflavones, in a dose-
219 dependent manner (5-10 μ M) (Fig. 1, Panel C). Cell viability of LPS stimulated cells resulted
220 significantly improved by treatment with tested milks, in a dose dependent manner (data not
221 shown).

222 3.2. Quantitative analysis of equol, daidzein and genistein from different samples by SPME-HPLC- 223 UV/DAD method

224 To clarify the role of equol, daidzein, genistein in the anti-inflammatory responses, firstly, their
225 concentration in bovine and soybean milks was determined by a SPME-HPLC analysis; then, *in*
226 *vitro* experiments were performed and compounds were also quantified in culture media and Caco-2
227 cells lysates, slightly modifying the previously validated method for the quantification of
228 compounds in milk.

229 Table 1 shows concentrations of analytes in milks before and after β -glucosidase deconjugation.

230

Insert Table 1

231 As evident, the predominant natural forms are sugar-conjugated, and lower concentrations of
232 aglycones were found in cow's milk compared to soy. Equol was never detected in the two milk
233 types.

234 Calibration curves were obtained for quantitative analysis of compounds in culture media.
235 Therefore, the method was validated in terms of linearity, limits of detection (LOD), quantification
236 (LOQ), precision, and repeatability.

237 The responses were found linear in the range of 0.05-15 μ M for all analytes, with correlation
238 coefficients always >0.999 and intercepts not significantly different from zero at the 95%
239 confidence level.

240 The estimated limits of detection (LOD) and quantification (LOQ) obtained, calculated as three and
241 ten fold the standard deviation of the intercept of each calibration curve, were 0.02 μ M for daidzein

242 and genistein and 0.03 μM for equol, and 0.07 μM for daidzein and genistein and 0.10 μM for
243 equol, respectively.

244 The precision of the method was investigated at the concentration levels of 0.5, 5 and 10 μM , by
245 performing daily three replicates (within day). The same solutions were analyzed for three times
246 each day, for a period of five days (between days). The within-day and between days precision of
247 the method, estimated by an ANOVA test, ranged from 3.1 to 3.7% and from 5.1 to 6.7%,
248 respectively. Average amounts of compounds in 5 or 10 μM culture media, picked up after 48 h
249 incubation by wells with Caco-2 cells plus LPS, were 23.0 ± 2.0 16.0 ± 1.8 and 2 ± 0.2 % of
250 estimated quantities in corresponding control wells (without Caco-2 cells and with LPS) for equol,
251 daidzein and genistein, respectively.

252 To certify absorption analytes by cells, equol, daidzein and genistein were checked in related
253 supernatants of cellular lysates. Given the complexity of the matrices, the method of standard
254 additions was used for SPME analysis.

255 Caco-2 cells pretreatments have produced the results listed in table 2, where concentrations of
256 compound are expressed in relation to total proteins estimated in each sample analyzed.

257 All amounts estimated are lower than expected, thus demonstrating their probable involvement in
258 cellular responses at stimulus.

259 In case of cellular pretreatments with soybean milk, the concentrations of isoflavones-aglycones in
260 culture media were found higher than original levels. For example, in culture media by Caco-2 cells
261 pretreated with 50 μl of soybean milk before of the stimuli with LPS, daidzein and genistein were
262 estimated at levels 2.54 ± 0.09 and 2.67 ± 0.10 μM , instead 0.23 ± 0.01 and 0.05 ± 0.01 μM of control,
263 respectively. Whereas, in respective cellular lysates, only genestein was found at level of 2.29
264 nmoles/mg of total proteins. Similar results were obtained also with the other amounts tested (10, 30
265 μL) of soy sample.

Insert Table 2

266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290

However, isoflavones-aglycones were not detected in samples related to bovine milk pretreatments, probably due to their lower biological contents in cow's milk.

3.3. NO production and iNOS expression.

Undetectable levels of NO production were observed in cell cultures treated with isoflavones alone (data not shown). In Caco-2 cells, LPS treatment significantly increased the level of NO as compared to untreated cells (control). A significant reduction ($p < 0.01$) of LPS-induced NO production was observed in cells submitted to 1h pre-treatment with isoflavones in comparison to cells treated with LPS alone; this effect was dose-dependent, where the maximal reduction ($p < 0.01$) was observed at 10 μM , as shown in Fig.2 (Panel A). In particular, from our results it emerged that both daidzein and genistein are more efficacious than equol in the reduction of LPS induced NO release.

We also investigated the effect of milks (bovine and soy) incubation on the NO release after LPS stimulation. Also in this case, 1h pre-treatment with milks, reduced LPS-induced NO production in a dose-dependent manner; the maximal reduction ($p < 0.01$) was observed with 50 μL milk (Fig.2 Panels B and C). In cell cultures treated with milk alone we observed NO levels comparable to those detected in controls.

In addition, RT-PCR data indicated that treatment with LPS significantly increased the expression of iNOS at 6 hours; however, pre-treatment with isoflavones resulted in a significant dose dependent decrease of the iNOS gene expression (Fig. 3, Panel A). Similar results were obtained in the experiments performed in the presence of commercial milks tested. Also in this case we observed that milks pretreated cells before LPS stimulation exhibited a significant dose-dependent reduction of iNOS mRNA expression in comparison to cells stimulated with LPS alone (Fig. 3, Panels B and C).

291 Consistent with the results of RT-PCR, western blot analysis showed that treatment with LPS
292 significantly increased iNOS protein synthesis at 48 hours; however, iNOS expression resulted
293 significantly down-regulated in the presence of compounds (Fig. 4, Panel A1). Similar results were
294 obtained in the experiments performed in the presence of tested commercial milks, where milk pre-
295 treatment of cell cultures determined a significant reduction of iNOS protein expression in
296 comparison to cells stimulated with LPS alone. Also in this case the effects were resulted dose
297 dependent (Fig. 4, Panels B1 and C1).

298 Taken together, these results indicate that isoflavones as well as milks, both bovine and soy, are
299 able to suppress the release of NO in LPS-stimulated intestinal cells modulating the expression of
300 iNOS both at transcriptional and at post-transcriptional levels.

301 *3.4. NF- κ B activity in LPS-induced intestinal cells*

302 Activation of NF- κ B is closely related to regulate the iNOS expression, in this regard the
303 phosphorylation and degradation of I κ B- α are essential in the translocation of NF- κ B p65 in the
304 nucleus from cytosol. Therefore, we determined the effect of our compounds on LPS-induced
305 degradation and phosphorylation of I κ B- α protein. For this purpose, we evaluated the expression of
306 p-I κ B in cell lysates obtained from LPS treated Caco-2 cells. In this context, we observed that cells
307 exposed to LPS exhibited a significant increase of I κ B- α expression as compared to unstimulated
308 cells, after 48 h of cell stimulation. Little phosphorylation of I κ B- α was observed in unstimulated
309 cells, as revealed by densitometric analysis (Fig. 4, Panels A2, B2, C2).

310 Pretreatment with isoflavones reduced, in a dose dependent manner, I κ B- α phosphorylation,
311 reaching a maximal reduction at 10 μ M (Fig. 4) in LPS stimulated Caco-2 cells (Fig. 4, panel A2).

312 Moreover, milk pre-treatment of LPS stimulated cells determined a dose-dependent inactivation of
313 the NF- κ B (Fig. 4, Panels B2 and C2).

314 Overall, these data indicate that both isoflavones and milks inhibited NF- κ B activity in LPS-
315 stimulated intestinal cells by suppressing degradation of I κ B- α , and, consequently, attenuating the
316 expression of iNOS mRNA.

317 4. DISCUSSION

318 The Caco-2 cell line, which is derived from human colon adenocarcinoma, exhibits enterocyte-like
319 characteristics and has been used widely as an *in vitro* model of absorption by intestinal epithelial
320 cells. Using Caco-2 cell line, we previously examined the cellular uptake and metabolism of milk
321 isoflavones. We found that compounds were taken up into Caco-2 cells and metabolized in accord
322 to previous works (Steenmsa et al., 2004).

323 Several analytical methods have been suggested for the determination of isoflavones and their
324 metabolic derivatives in biological fluids and food matrices. (Antignac et al., 2004; de Rijke et al.,
325 2006; Rostagno et al., 2009, Aresta et al., 2015) Solid phase microextraction is a widespread sample
326 preparation technique that allows a solventless extraction of the target compounds. Recently, it has
327 proposed a new simple, selective, sensible, accurate and low cost method for the determination of
328 major isoflavones in soy drinks based on SPME coupled with liquid chromatography (Aresta et al.,
329 2015). In this study, all SPME – HPLC-UV/DAD parameters suggested have been carefully
330 considered and applied, obtaining results comparable to previous works. Equol was not detected in
331 two types of milk. However, according to literature data, it is not a natural component of vegetable
332 milks, unlike those of bovine, whose levels range from 0.236 ± 0.004 to $4.140\pm 0.152\mu\text{M}$, quantities
333 lower or near to LOD of method used (Antignac et al., 2004; Di Cagno et al., 2010).

334 The intestinal cells are also able to mount an adequate inflammatory response, by releasing of pro-
335 inflammatory mediators, such as cytokines and free radicals, to protect against infections (Caricilli
336 et al., 2014). However, when excessive, inflammatory responses may alter the homeostasis of the
337 intestinal mucosa, destroying the intestinal epithelial monolayer. The reactive NO is a major
338 mediator of the inflammatory responses. NO is enzymatically generated in a variety of cells from L-

339 arginine pathway by three isoforms of NO synthetase. Three major isoforms of nitric oxide synthase
340 include neuronal, endothelial and inducible nitric oxide synthase (nNOS, eNOS and iNOS,
341 respectively). The iNOS form is calcium independent and inducible by inflammatory cytokines and
342 bacterial products, such as LPS, in various cell types, including intestinal cells. Increased
343 expression of iNOS leads to synthesis of micromolar quantities of NO, which causes damage to
344 cells and tissues through the formation of NO-reactive products, used as measurement for toxicity
345 marker (sHaug et al., 2007). NO-induced oxidative stress is associated with many diseases,
346 including IBD. Excessive production of NO, and the presence of nitric oxide synthase protein and
347 iNOS mRNA have been observed in intestinal mucosa of affected areas in patients with ulcerative
348 colitis and Crohn's disease (Ikeda et al., 1997). This is consistent with data obtained from animal
349 models of inflammatory bowel disease (Kankuri et al., 1999). Nitric oxide, in conjunction with
350 superoxide anion, generates significant amounts of peroxynitrite anion, a potent oxidizing agent,
351 which inflicts cellular injury and necrosis probably via mechanisms including DNA fragmentation
352 and lipid oxidation (Valko et al., 2007). For these reasons, down-regulation of NO has been used to
353 treat such diseases (Lanas et al., 2008). The anti-inflammatory agents, such as anti-inflammatory
354 drugs (NSAIDs), have been widely used to treat inflammation-associated diseases. However, using
355 NSAIDs to inhibit the expression of iNOS and NO can lead to severe gastrointestinal damage
356 (Sasso et al., 2015). As a result, NSAIDs use is actually avoided for the treatment of IBD. Searching
357 for effective treatments is urgent needed for the development of therapies and for the prevention of
358 IBD. Many people with IBD turn to alternative medicine including traditional plant based remedies.
359 In the current study, we found that equol, daidzein and genistein, isoflavones, which are present as
360 natural components of milk, down-regulate the release of NO as well as the expression of iNOS
361 mRNA and protein in LPS-stimulated intestinal cells in a dose-dependent manner. These effects on
362 the LPS induced NO production were also observed in Caco-2 cells pre-treated with bovine and soy
363 milks prior LPS stimulation. Similar results were obtained by Di Cagno et al., (2010) reporting that

364 soy milk as well as equol, genistein and daidzein, markedly inhibited the inflammatory status of
365 Caco-2/TC7 cells as induced by treatment with interferon- γ and LPS, although the exact molecular
366 mechanism responsible for this action is not reported.

367 Interestingly, we also observed that isoflavones treatment, as well as milks treatment, of LPS
368 stimulated cells is able to reduce, although not completely depress, NO production, which remained
369 yet significantly higher in comparison with control cells. This result is consistent with previous
370 studies reporting NO to play a protective role in the intestinal epithelium (Wallace & Miller, 2000;
371 Zhang, Urbanski, & McCafferty, 2007). In this respect it was reported that in the iNOS-deficient
372 mice iNOS induction the sites of intestinal injury result protective rather than detrimental, since an
373 increase in the macroscopic damage was seen during acute phase of the experimentally-induced
374 colitis (McCafferty et al., 1997). These data suggest that induction of iNOS plays a critical role in
375 the healing and in the gut inflammatory processes. Consequently, a controlled NO production by
376 intestinal cells may contribute to the normal homeostasis of the intestinal epithelium.

377 It has been reported that NF- κ B plays a critical role in the IBD, and previous studies showed that
378 NF- κ B inhibitors suppress pro-inflammatory responses thus ameliorating the clinical scenario (Sun
379 et al., 2015). In this context, it is well accepted that several natural antioxidants, such as polyphenol
380 compounds, mediate anti-inflammatory activities by directly suppressing the expression of NF- κ B
381 dependent pro-inflammatory mediators, including iNOS (Panaro et al., 2012; Bai et al., 2005;
382 Kumar, Takada, Boriek, & Aggarwal, 2004).

383 Therefore, blockade of NF- κ B signal transduction pathways may be one of the major mechanisms
384 underlying the prevention of the development of IBD.

385 The isoflavones, daidzein and genistein, have been reported to inhibit iNOS protein and mRNA
386 expression and NO production in LPS induced murine J774 macrophages in a dose-dependent
387 manner down-regulating the NF- κ B activation (Hämäläinen et al., 2007). Protective effects of
388 genistein are also demonstrated in other experimental models. For example Valles et al. (2010) have

389 found that genistein in astrocytes in primary culture attenuates inflammation, preventing the
390 expression of inflammatory mediators, including iNOS. Also Comalada et al. (2006) have indicated
391 that flavonoids inhibit TNF- α production as well as iNOS expression and NO production in LPS-
392 activated macrophages, an effect associated with the inhibition of the NF- κ B pathway. Furthermore,
393 Lu et al. (2009), investigating the anti-inflammatory properties of genistein in primary astrocytes
394 treated with hemolysate, demonstrated that genistein inhibited the expression of iNOS and COX-2
395 mRNA and the level of hemolysate-stimulated NF- κ B.

396 Finally, other results demonstrate that equol is able to impair LPS-induced NO production and
397 iNOS gene expression in RAW 264.7 murine macrophage and that these effects are mediated, at
398 least in part, through NF- κ B activity inhibition (Kang et al., 2007).

399 The present study demonstrated that isoflavones tested, as well as bovine and soy milks, attenuate
400 NO production in LPS activated intestinal cells, interfering to NF- κ B activation. In particular we
401 observed that natural compounds used in this study, genistein, daidzein and equol, were able to
402 reduce in a dose dependent manner NF- κ B activation, thus leading to mRNA and protein reduced
403 expression in LPS intestinal cells.

404 Many milk-derived components have immunomodulatory and anti-inflammatory properties, and
405 some of these reduce intestinal inflammation when orally administered to animal models of colitis.
406 The most commonly consumed milk in Western countries is bovine milk. Like human milk, bovine
407 milk contains a number of potentially beneficial bioactivities, as well as carbohydrate (including
408 lactose and oligosaccharides), vitamins, minerals and antioxidants (Haug et al., 2007).

409 However, milk composition varies between different species (Haug et al., 2007) and is affected by
410 nutrition and health status (Mele et al., 2009), which depends on a variety of factors, such as
411 genotype, milk protein allergies, or lactose intolerance (Haug et al., 2007). In this regard, the IBD
412 patients are often likely to eliminate milk from their diet due to a widespread belief that is
413 deleterious, using milk substitutes soy-based, that have been shown more beneficial compared to

414 cow's milk. This could lead to the commercialization of soy as a healthy alternative to milk. For
415 IBD patients who can tolerate dairy products, milk may provide a valuable nutritional support.
416 Some components of milk, such as equol, may also have beneficial actions in the control of the
417 inflammatory status of the gut, although these components may not be present in concentrations
418 high enough to provide substantial benefits. The impact of milk on human health and the
419 functionality of each bioactive component need to be further investigated, so that the use of bovine
420 or soy milk as well as of the milk components, as isoflavones, in the diet can be optimised to
421 provide maximum benefits for intestinal inflammation, thus minimizing adverse effects.

422 **Conclusions**

423 In conclusion, our actual findings indicate that isoflavones present in the milk are able to control
424 LPS-induced NO production down-regulating iNOS expression in activated intestinal cells. This
425 action seems to be directly attributable to the selective inhibition of NF-kB signaling pathway, thus
426 providing the first molecular description of the anti-inflammatory properties of isoflavones in an in
427 vitro model of IBD. As a result, our data represent a valid rationale for the use of isoflavone-
428 enriched milks as a complementary approach, with lower incidence of side effects, during the
429 management of IBD. However, additional in vivo research is needed in vivo to confirm these results
430 in order to suggest the use of isoflavone-enriched milks as functional beverages for medical
431 purposes.

432432

433 REFERENCES:

- 434 Andres, S., Abraham, K., Appel, K.E., & Lampen, A. (2011). Risks and benefits of dietary
435 isoflavones for cancer. *Critical Reviews in Toxicology*, 41(6), 463-506.
- 436 Antignac, J.P., Cariou, R., Bizec, B.L., & Andre, F. (2004). New data regarding phytoestrogens
437 content in bovine milk. *Food Chemistry*, 87, 275–281.
- 438 Aresta, A., Di Grumo, F., & Zambonin, C. (2015). Determination of major isoflavones in soy drinks
439 by solid-phase micro extraction coupled to liquid chromatography. DOI: 10.1007/s12161-015-
440 0260-1
- 441 Bai, S.K., Lee, S.J., Na, H.J., Ha, K.S., Han, J.A., Lee, H., Kim, Y.M. (2005). beta-Carotene
442 inhibits inflammatory gene expression in lipopolysaccharide-stimulated macrophages by
443 suppressing redox-based NF-kappaB activation. *Experimental & Molecular Medicine*, 37(4), 323-
444 334.
- 445 Bradford, M.M. (1976). A rapid and sensitive method for the quantitation of microgram quantities
446 of protein utilizing the principle of protein-dye binding. *Analytical Biochemistry*, 72, 248–254.
- 447 Caldarelli, A., Diel, P., & Vollmer, G. (2005). Effect of phytoestrogens on gene expression of
448 carbonic anhydrase II in rat uterus and liver. *The Journal of Steroid Biochemistry and Molecular
449 Biology*, 97(3), 251–256.
- 450 Caricilli, A.M., Castoldi, A., & Câmara, N.O. (2014). Intestinal barrier: A gentlemen's agreement
451 between microbiota and immunity. *World Journal of Gastrointestinal Pathophysiology*, 5(1), 18-32.
- 452 Cianciulli, A., Calvello, R., Cavallo, P., Dragone, T., Carofiglio, V., & Panaro M.A. (2012).
453 Modulation of NF-κB activation by resveratrol in LPS treated human intestinal cells results in
454 downregulation of PGE2 production and COX-2 expression. *Toxicology In Vitro*, 26(7), 1122-
455 1128.
- 456 Comalada, M., Ballester, I., Bailón, E., Sierra, S., Xaus, J., Gálvez, J., Zarzuelo, A. (2006).
457 Inhibition of pro-inflammatory markers in primary bone marrow-derived mouse macrophages by
458 naturally occurring flavonoids: analysis of the structure–activity relationship. *Biochemical
459 Pharmacology*, 72(8), 1010–1021.
- 460 de Rijke, E., Out, P., Niessen, W.M., Ariese, F., Gooijer, C., & Brinkman, U.A. (2006). Analytical
461 separation and detection methods for flavonoids. *Journal of Chromatography. A*, 1112(1-2), 31-63.
- 462 Di Cagno, R., Mazzacane, F., Rizzello, C.G., Vincentini, O., Silano, M., Giuliani, G., De Angelis,
463 M., & Gobbetti, M. (2010) Synthesis of isoflavone aglycones and equol in soy milks fermented by
464 food-related lactic acid bacteria and their effect on human intestinal Caco-2 cells. *J. Agric. Food
465 Chem.*, 58 (19), 10338-10346.
- 466 Ganai, A.A., Khan, A.A., Malik, Z.A., & Farooqi, H. (2015). Genistein modulates the expression of
467 NF-κB and MAPK (p-38 and ERK1/2), thereby attenuating d-Galactosamine induced fulminant
468 hepatic failure in Wistar rats. *Toxicology and Applied Pharmacology*, 283(2), 139-146.
- 469 Hämäläinen, M., Nieminen, R., Vuorela, P., Heinonen, M., & Moilanen E. (2007). Anti-
470 inflammatory effects of flavonoids: genistein, kaempferol, quercetin, and daidzein inhibit STAT-1
471 and NF-kappaB activations, whereas flavone, isorhamnetin, naringenin, and pelargonidin inhibit
472 only NF-kappaB activation along with their inhibitory effect on iNOS expression and NO
473 production in activated macrophages. *Mediators Inflammation*, 2007, 45673.

474 Haug, A., Hostmark, A.T., & Harstad, O.M., (2007). Bovine milk in human nutrition—a review.
 475 *Lipids in Health and Disease*, 6-25.

476 Havsteen, B. H. (2002). The biochemistry and medical significance of the flavonoids. *Pharmacology*
 477 *& Therapeutics*, 96(2-3), 67–202.

478 Ikeda, I., Kasajima, T., Ishiyama, S., Shimojo, T., Takeo, Y., Nishikawa, T., Mitsunaga, A. (1997).
 479 Distribution of inducible nitric oxide synthase in ulcerative colitis. *The American Journal of*
 480 *Gastroenterology*, 92(8), 1339-1341.

481 Kang, J.S., Yoon, Y.D., Han, M.H., Han, S.B., Lee, K., Park, S.K., & Kim, H.M. (2007). Equol
 482 inhibits nitric oxide production and inducible nitric oxide synthase gene expression through down-
 483 regulating the activation of Akt. *International Immunopharmacology*, 7(4), 491-499.

484 Kankuri, E., Asmawi, M.Z., Korpela, R., Vapaatalo, H., & Moilanen, E. (1999). Induction of iNOS
 485 in a rat model of acute colitis. *Inflammation*, 23(2), 141-152.

486 Kaser, A., Zeissig, S., Blumberg, R.S. (2010). Inflammatory bowel disease. *Annual Review of*
 487 *Immunology*, 28, 573-621.

488 Kumar, A., Takada, Y., Boriek, A.M., & Aggarwal, B.B. (2004). Nuclear factor-kappaB: Its role in
 489 health and disease. *Journal of Molecular Medicine*, 82, 434–448.

490 Lanas, A. (2008). Role of nitric oxide in the gastrointestinal tract. *Arthritis Research & Therapy*,
 491 10(2), S4.

492 Lu, H., Shi, J.X., Zhang, D.M., Wang, H.D., Hang, C.H., Chen, H.L., & Yin, H.X. (2009).
 493 Inhibition of hemolysate-induced iNOS and COX-2 expression by genistein through suppression of
 494 NF- κ B, C/EBP β activation in primary astrocytes. *Journal of the Neurological Sciences*,
 495 278(1-2), 91–95.

496 McCafferty, D.M., Mudgett, J.S., Swain, M.G., & Kubes, P. (1997). Inducible nitric oxide synthase
 497 plays a critical role in resolving intestinal inflammation. *Gastroenterology*, 112(3), 1022-1027.

498 Mele, M., Dal Zotto, R., Cassandro, M., Conte, G., Serra, A., Buccioni, A., Secchiari, P. (2009).
 499 Genetic parameters for conjugated linoleic acid, selected milk fatty acids, and milk fatty acid
 500 unsaturation of Italian Holstein-Friesian cows. *Journal of Dairy Science*, 92(1), 392-400.

501 Panaro, M.A., Carofiglio, V., Acquafredda, A., Cavallo, P., & Cianciulli, A. (2012). Anti-
 502 inflammatory effects of resveratrol occur via inhibition of lipopolysaccharide-induced NF- κ B
 503 activation in Caco-2 and SW480 human colon cancer cells. *British Journal of Nutrition*, 108(9),
 504 1623-1632.

505 Park, C.E., Yun, H., Lee, E.B., Min, B.I., Bae, H., Choe, W., Ha, J. (2010). The antioxidant effects
 506 of genistein are associated with AMP-activated protein kinase activation and PTEN induction in
 507 prostate cancer cells. *Journal of Medicinal Food*, 13(4), 815–820.

508 Rostagno, M.A., Villares, A., Guillamón, E., García-Lafuente, A., & Martínez, J.A. (2009). Sample
 509 preparation for the analysis of isoflavones from soybeans and soy foods. *Journal of*
 510 *chromatography. A*, 1216(1), 2-29.

511 Rusin, A., Krawczyk, Z., Gryniewicz, G., Gogler, A., Zawisza-Puchalka, J., & Szeja, W., (2010).
 512 Synthetic derivatives of genistein, their properties and possible applications. *Acta Biochimica*
 513 *Polonica*, 57(1), 23–34.

514 Sarkar, F.H., & Li, Y. (2003). Soy isoflavones and cancer prevention. *Cancer Investigation*, 21(5),
 515 744-757.

516 Sasso, O., Migliore, M., Habrant, D., Armirotti, A., Albani, C., Summa, M., Piomelli, D. (2015).
517 Multitarget fatty acid amide hydrolase/cyclooxygenase blockade suppresses intestinal inflammation
518 and protects against nonsteroidal anti-inflammatory drug-dependent gastrointestinal damage. *The*
519 *FASEB Journal*, 29(6), 2616-2627.

520 Steensma, A., Noteborn, H.P., & Kuiper, H.A. (2004). Comparison of Caco-2, IEC-18 and HCEC
521 cell lines as a model for intestinal absorption of genistein, daidzein and their glycosides.
522 *Environmental Toxicology and Pharmacology*, 16(3), 131–139.

523 Sun, Y., Zhao, Y., Yao, J., Zhao, L., Wu, Z., Wang, Y., Lu N. (2015). Wogonoside protects against
524 dextran sulfate sodium-induced experimental colitis in mice by inhibiting NF- κ B and NLRP3
525 inflammasome activation. *Biochemical Pharmacology*, 94(2), 142-154.

526 Valles, S.L., Dolz-Gaiton, P., Gambini, J., Borrás, C., Lloret, A., Pallardo, F.V., & Viña, J. (2010).
527 Estradiol or genistein prevent Alzheimer's disease-associated inflammation correlating with an
528 increase PPAR gamma expression in cultured astrocytes. *Brain Research*, 1312, 138-144.

529 Valko, M., Leibfritz, D., Moncol, J., Cronin, M.T., Mazur, M., & Telser, J. (2007). Free radicals
530 and antioxidants in normal physiological functions and human disease. *The International Journal*
531 *Biochemistry & Cell Biology*, 39(1), 44-84.

532 Wallace, J.L., & Miller, M.J.S. (2000). Nitric oxide in mucosal defense: a little goes along way.
533 *Gastroenterology*, 119(2), 512–520., K., Kushima, R., Kisaki, O., Fujiyama, Y., & Okabe, H.
534 (2003). Combined effect of hydrogen peroxide induced oxidative stress and IL-1 alpha on IL-8
535 production in CaCo-2 cells (a human colon carcinoma cell line) and normal intestinal epithelial
536 cells. *Inflammation*, 27(3), 123-128.

537 Zhang, R., Ma, A., Urbanski, S.J., & McCafferty, D.M. (2007). Induction of inducible nitric oxide
538 synthase: a protective mechanism in colitis-induced adenocarcinoma. *Carcinogenesis*, 28(5), 1122-
539 1130.

540 Zhang, Y., Chen, W.F., Lai, W.P., & Wong, M.S. (2008). Soy isoflavones and their boneprotective
541 effects. *Inflammopharmacology* 16(5), 213–215.

542

543 Table and Figure Captions

544 Table 1

545 Concentration of isoflavones-aglycones in two commercial bovine and soybeans milks before and
546 after β -glucosidase deconjugation.

547 Table 2

548 Concentration of proteins and analytes in Caco-2 cells lysates.

549 Figure 1

550 Cell viability assessed by MTT assay. Panel A: Caco-2 cells were incubated (48 h) in the presence
551 of different concentrations of isoflanones (5-50 μ M). Panel B: Caco-2 cells were incubated in
552 absence (control) or in presence of LPS (0,5-1 μ g/mL). Panel C: cells were stimulated with LPS
553 alone or after pre-treatment of isoflavones. Ctr: control; LPS: LPS-treated cells. Data, expressing
554 the percentage of cell viability, are reported as means \pm SD of five independent experiments. * p <
555 0.05; ** p < 0.01 compared with the control value (medium); # p < 0.01 versus LPS alone.

556 Figure 2

557 NO release in Caco-2 cells. Panel A: intestinal cells were exposed to LPS alone or after 1h pre-
558 treatment with isoflavones. Panel B: effect of bovine milk (B) treatment (see in the text for
559 concentration and time used) on NO release; Panel C: effect of soy milk (S) treatment (see in the
560 text) on NO. Ctr: control; LPS: LPS-treated cells Results are expressed as means \pm SD of five
561 independent experiments. E: equol; D: daidzein; G: genistein. * p < 0.01 versus control value
562 (medium); # p < 0.01 versus LPS alone; § p < 0.05 and §§ p < 0.01 between LPS+isoflavones or
563 LPS+milks.

564 Figure 3.

565 iNOS mRNA expression. Panel A: intestinal cells were treated with LPS alone or after 1h pre-
566 treatment of isoflavones. Panel B: iNOS mRNA expression in Caco-2 cells treated with bovine milk
567 (B) alone or in presence of LPS; Panel C: iNOS mRNA expression in Caco-2 cells treated with soy

568 milk (S) in absence or in presence of LPS. Values represent the mRNA fold changes relative to β -
569 actin used as resident control and expressed as means \pm SD of five independent experiments. Ctr:
570 control; LPS: LPS-treated cells; E: equol; D: daidzein; G: genistein. * $p < 0.01$ compared with the
571 control value (medium); # $p < 0.01$ versus LPS alone; § $p < 0.05$ and §§ $p < 0.01$ between
572 LPS+isoflavones or LPS+milks.

573 **Figure 4**

574 Western blot analysis of iNOS in Caco-2 cells. Panel A1: intestinal cells were treated with LPS
575 alone or after 1h pre-treatment of isoflavones. Panel B1: Caco-2 cells were treated with bovine milk
576 (B) alone or in presence of LPS. Panel C1: Caco-2 cells treated with soy milk (S) in absence or in
577 presence of LPS. Protein expression levels were normalized to β -actin and results of densitometric
578 analysis are expressed as means \pm SD of five independent experiments. E: equol; D: daidzein; G:
579 genistein; Ctr: control; LPS: LPS-treated cells * $p < 0.01$ compared with the control value (medium);
580 # $p < 0.01$ versus LPS alone; § $p < 0.05$ and §§ $p < 0.01$ between LPS+isoflavones or LPS+milks.

581 Signalling pathway analysis. Panel A2: Western blot analysis of p-I κ B α in Caco-2 cells treated with
582 LPS alone or after 1h pre-treatment of isoflavones. E: equol; D: daidzein; G: genistein. Panel B2:
583 Immunoblot analysis of p-I κ B α in Caco-2 cells treated with bovine milk (B) alone or in presence of
584 LPS. Panel C2: Immunoblotting analysis of cells treated with soy milk (S) in absence or in presence
585 of LPS. Protein expression levels were normalized to β -actin and results of densitometric analysis
586 are expressed as means \pm SD of five independent experiments. * $p < 0.01$ compared with the control
587 value (medium); # $p < 0.01$ versus LPS alone; § $p < 0.05$ and §§ $p < 0.01$ between LPS+isoflavones or
588 LPS+milks.

589589

Highlights

1. milks and bioactive compounds tested are able to reduce LPS-induced inflammatory responses
2. B and SB milk bioactive compounds significantly inhibited the expression of (iNOS) mRNA
3. B and SB milk bioactive compounds significantly inhibited protein expression
4. the inhibition is dose-dependent
5. bioactive compounds were absorbed, metabolized and released by Caco-2 cells in culture media

Isoflavones	Soybean milk		Bovine milk	
	before	after	before	after
Daidzein	3.6± 0.3 μM	160.7± 13.5 μM	0.06± 0.01 μM	0.12± 0.05 μM
Genistein	0.9± 0.1 μM	121.8± 12.1 μM	0.03± 0.01 μM	0.04± 0.01 μM

Table 1

Pretreatment		[proteins] (mg/mL)	[analyte] _{found} (nmoles/mg proteins)
equol	5 μ M	8.6 \pm 0.5	0.44 \pm 0.25
	10 μ M	6.8 \pm 0.3	1.16 \pm 0.54
daidzein	5 μ M	9.4 \pm 0.6	0.46 \pm 0.19
	10 μ M	18.4 \pm 1.5	0.44 \pm 0.36
genistein	5 μ M	17.0 \pm 1.2	0.28 \pm 0.15
	10 μ M	19.6 \pm 1.6	0.49 \pm 0.28

Table 2









